40 related articles for article (PubMed ID: 36222132)
1. SMYD3 drives the proliferation in gastric cancer cells via reducing EMP1 expression in an H4K20me3-dependent manner.
Zeng Y; Ma G; Cai F; Wang P; Liang H; Zhang R; Deng J; Liu Y
Cell Death Dis; 2023 Jun; 14(6):386. PubMed ID: 37386026
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Calcium-Activated Chloride Channel ANO1/TMEM16A Suppresses Tumor Growth and Invasion in Human Lung Cancer.
Jia L; Liu W; Guan L; Lu M; Wang K
PLoS One; 2015; 10(8):e0136584. PubMed ID: 26305547
[TBL] [Abstract][Full Text] [Related]
3. The SMYD3-dependent H3K4me3 status of IGF2 intensifies local Th2 differentiation in CRSwNP via positive feedback.
Yu L; Wei Y; Lu T; Li Z; Lai S; Yan Y; Chen C; Wen W
Cell Commun Signal; 2023 Nov; 21(1):345. PubMed ID: 38037054
[TBL] [Abstract][Full Text] [Related]
4. Enhanced SMYD3 expression is essential for the growth of breast cancer cells.
Hamamoto R; Silva FP; Tsuge M; Nishidate T; Katagiri T; Nakamura Y; Furukawa Y
Cancer Sci; 2006 Feb; 97(2):113-8. PubMed ID: 16441421
[TBL] [Abstract][Full Text] [Related]
5. Low dose cadmium exposure regulates miR-381-ANO1 interaction in airway epithelial cells.
Singh P; Li FJ; Dsouza K; Stephens CT; Zheng H; Kumar A; Dransfield MT; Antony VB
Sci Rep; 2024 Jan; 14(1):246. PubMed ID: 38168913
[TBL] [Abstract][Full Text] [Related]
6. THAP3 recruits SMYD3 to OXPHOS genes and epigenetically promotes mitochondrial respiration in hepatocellular carcinoma.
Wang ZH; Wang J; Liu F; Sun S; Zheng Q; Hu X; Yin Z; Xie C; Wang H; Wang T; Zhang S; Wang YP
FEBS Lett; 2024 Apr; ():. PubMed ID: 38664231
[TBL] [Abstract][Full Text] [Related]
7. The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer.
Ikram S; Rege A; Negesse MY; Casanova AG; Reynoird N; Green EM
Sci Adv; 2023 Nov; 9(46):eadi5921. PubMed ID: 37976356
[TBL] [Abstract][Full Text] [Related]
8. SMYD3 activates the TCA cycle to promote M1-M2 conversion in macrophages.
Zhu W; Liu L; Wu J; Gao R; Fu L; Yang X; Zou Y; Zhang S; Luo D
Int Immunopharmacol; 2024 Jan; 127():111329. PubMed ID: 38091832
[TBL] [Abstract][Full Text] [Related]
9. The role of anoctamin 1 in liver disease.
Li X; Wang Y; Zhang L; Yao S; Liu Q; Jin H; Tuo B
J Cell Mol Med; 2024 May; 28(9):e18320. PubMed ID: 38685684
[TBL] [Abstract][Full Text] [Related]
10. SET and MYND domain-containing protein 3 inhibits tumor cell sensitivity to cisplatin.
Wang L; Xu ML; Wang C; Dong QQ; Miao Z; Chen XY; Wang N; He HP; Zhang TC; Luo XG
Oncol Lett; 2020 May; 19(5):3469-3476. PubMed ID: 32269620
[TBL] [Abstract][Full Text] [Related]
11. LXR Signaling-Mediated Cholesterol Metabolism Reprogramming Regulates Cancer Cell Metastasis.
Singh PK; Mehla K
Cancer Res; 2023 Jun; 83(11):1759-1761. PubMed ID: 37264829
[TBL] [Abstract][Full Text] [Related]
12. CXXC finger protein 1 (CFP1) bridges the reshaping of genomic H3K4me3 signature to the advancement of lung adenocarcinoma.
Fan T; Xiao C; Liu H; Liu Y; Wang L; Tian H; Li C; He J
Signal Transduct Target Ther; 2023 Sep; 8(1):369. PubMed ID: 37735441
[TBL] [Abstract][Full Text] [Related]
13. SMYD3-associated pathway is involved in the anti-tumor effects of sulforaphane on gastric carcinoma cells.
Dong QQ; Wang QT; Wang L; Jiang YX; Liu ML; Hu HJ; Liu Y; Zhou H; He HP; Zhang TC; Luo XG
Food Sci Biotechnol; 2018 Aug; 27(4):1165-1173. PubMed ID: 30263847
[TBL] [Abstract][Full Text] [Related]
14. The chromatin remodeling factors EP300 and TRRAP are novel SMYD3 interactors involved in the emerging 'nonmutational epigenetic reprogramming' cancer hallmark.
Fasano C; Lepore Signorile M; Di Nicola E; Pantaleo A; Forte G; De Marco K; Sanese P; Disciglio V; Grossi V; Simone C
Comput Struct Biotechnol J; 2023; 21():5240-5248. PubMed ID: 37954147
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel natural compound, vitekwangin B, with ANO1 protein reduction properties and anticancer potential.
Seo Y; Lee S; Kim M; Kim D; Jeong SB; Das R; Sultana A; Park S; Nhiem NX; Huong PTT; Kwon OB; Namkung W; Woo J
Front Pharmacol; 2024; 15():1382787. PubMed ID: 38659592
[No Abstract] [Full Text] [Related]
16. Role and potential therapeutic value of histone methyltransferases in drug resistance mechanisms in lung cancer.
Zhang L; Zhang X; Shi Y; Ni Y; Fei J; Jin Z; Li W; Wang X; Wu N
Front Oncol; 2024; 14():1376916. PubMed ID: 38525426
[TBL] [Abstract][Full Text] [Related]
17. SMYD3 regulates the abnormal proliferation of non-small-cell lung cancer cells via the H3K4me3/ANO1 axis.
Zhong D; Zhan Z; Zhang J; Liu Y; He Z
J Biosci; 2022; 47():. PubMed ID: 36222132
[TBL] [Abstract][Full Text] [Related]
18. SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non‑small cell lung cancer.
Li J; Zhao L; Pan Y; Ma X; Liu L; Wang W; You W
Int J Oncol; 2020 Sep; 57(3):756-766. PubMed ID: 32705243
[TBL] [Abstract][Full Text] [Related]
19. Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription.
Yang Z; Liu F; Li Z; Liu N; Yao X; Zhou Y; Zhang L; Jiang P; Liu H; Kong L; Lang C; Xu X; Jia J; Nakajima T; Gu W; Zheng L; Zhang Z
Clin Epigenetics; 2023 May; 15(1):92. PubMed ID: 37237385
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
